Loading
Amivantamab / Osimertinib / Carcinoma, Non Small Cell Lung · Phase 3 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 3 trial registry record comparing amivantamab plus lazertinib against osimertinib as first-line therapy in EGFR-mutant advanced NSCLC. No efficacy or safety results are posted in this registry entry; the study is closed to recruitment but outcomes remain unreported.
Phase 3, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Carcinoma, Non-Small-Cell Lung; age from 18 Years. Intervention: Treatment Arm A (Open-label): Amivantamab and Lazertinib; Treatment Arm C (Double-blind): Lazertinib+Placebo Osimerti…. Compared with: Treatment Arm B (Double-blind): Osimertinib+Placebo Lazerti… — Active Comparator. n = 1,074. 269 sites across 28 countries.
This is a Phase 3 trial registry record comparing amivantamab plus lazertinib against osimertinib as first-line therapy in EGFR-mutant advanced NSCLC. No efficacy or safety results are posted in this registry entry; the study is closed to recruitment but outcomes remain unreported.
This is a registry record with no results posted; efficacy, safety, and tolerability data are not reported
The source did not state who this applies to in practice.
This is a Phase 3 RCT registry record with no posted results; the study is active but not recruiting, and outcomes remain unreported in this source.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04487080). This is a study registration, not published results. Lead sponsor: Janssen Research & Development, LLC. Recruitment status: ACTIVE_NOT_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 1074 participants (ACTUAL). Conditions: Carcinoma, Non-Small-Cell Lung. Interventions: DRUG: Amivantamab; DRUG: Osimertinib; DRUG: Lazertinib; DRUG: Placebo. Primary outcome measures: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) , From randomization to either disease progression or death whichever occurs first (up to 32.8 months). Brief summary: The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.